Company: LIMN
Filing Date: 2025-01-27
Form Type: POS AM
Source: 0001104659-25-006325
Chunk: 455

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-27
Form: POS AM
Chunk 455
---
, $0.0001 par value; 280,000,000 shares authorized;6,900,000 and 0 shares issued and outstanding (excluding 406,609 and1,413,104 shares subject to possible redemption) at December 31, 2023and December 31, 2022, respectively | ​ | ​ | ​            | ​ |         690 | ​ | ​ | ​ | ​    | ​ |           — | ​ | ​ |
| Class B common stock, $0.0001 par value; 20,000,000 shares authorized; 0and 6,900,000 shares issued and outstanding at December 31, 2023 andDecember 31, 2022, respectively                                                                         | ​ | ​ | ​            | ​ |           — | ​ | ​ | ​ | ​    | ​ |         690 | ​ | ​ |
| Additional paid-in capital                                                                                                                                                                                                                          | ​ | ​ | ​            | ​ |     140,000 | ​ | ​ | ​ | ​    | ​ |     140,000 | ​ | ​ |
| Accumulated deficit                                                                                                                                                                                                                                 | ​ | ​ | ​            | ​ | -14,883,124 | ​ | ​ | ​ | ​    | ​ | -13,974,105 | ​ | ​ |
| Total Stockholders’ Deficit                                                                                                                                                                                                                         | ​ | ​ | ​            | ​ | -14,742,434 | ​ | ​ | ​ | ​    | ​ | -13,833,415 | ​ | ​ |
| Total Liabilities, Common Stock Subject to Possible Redemption and Stockholders’ Deficit                                                                                                                                                            | ​ | ​ | ​            | $ |   4,502,213 | ​ | ​ | ​ | ​    | $ |  15,488,270 | ​ | ​ |

(1) As of December 31, 2023, $85,084 of the $156,425 cash balance is classified as restricted cash to be used for tax payments only.

The accompanying notes are an integral part of these financial statements. F-29

TABLE OF CONTENTS

IRIS ACQUISITION CORP
STATEMENTS OF OPERATIONS

| ​                                                                                                          
 ​                                                                                                          | ​ 
 ​ | ​ 
 ​ | For the years ended December 31, 
 2023                             |   |            |   | ​ | ​ | 2022 |   |            |   | ​